RON antibody - Agency for Science, Technology and Research/ ASLAN Pharmaceuticals
Latest Information Update: 24 Oct 2016
At a glance
- Originator Agency for Science, Technology and Research
- Class Antibodies; Antineoplastics
- Mechanism of Action RON protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer